Federal Register / Vol. 74, No. 59 / Monday, March 30, 2009 / Notices 14141 

5. AM Klutz, ZG Gao, J Lloyd, A 

Shainberg, KA Jacobson. Enhanced A3

adenosine receptor selectivity of 

multivalent nucleoside-dendrimer 

conjugates. J Nanobiotechnol. 2008 Oct 

23;6:12. 

Patent Status 

• U.S. Provisional Application No. 

60/947,121 filed 20 Jun 2007 (HHS 

Reference No. E–219–2007/0–US–01). 

• U.S. Provisional Application No. 

61/045,498 filed 16 Apr 2008 (HHS 

Reference No. E–219–2007/1–US–01). 

• International Application No. PCT/ 

US08/067683 filed 20 Jun 2008, which 

published as WO2009/006046 on 08 Jan 

2009 (HHS Reference No. E–219–2007/ 

2–PCT–01). 

• U.S. Patent Application No.12/ 

143,451 filed 20 Jun 2008, which 

published as U.S. 20090012035 on 08 

Jan 2009 (HHS Reference No. E–219– 

2007/2–US–02). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Cristina 

Thalhammer-Reyero, PhD, MBA; 301– 

435–4507; thalhamc@mail.nih.gov. 

Collaborative Research Opportunity: 

The Laboratory of Bioorganic Chemistry 

of the National Institute of Diabetes & 

Digestive & Kidney Diseases is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize dendrimer conjugates of 

suitably functionalized small molecule 

ligands of adenosine receptors and P2Y 

nucleotide receptors. Please contact Dr. 

Kenneth A. Jacobson at 301–496–9024, 

or e-mail kajacobs@helix.nih.gov, for 

more information. 

Dated: March 19, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–6935 Filed 3–27–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

Federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

M2e Peptide Vaccine Against Influenza 

Virus 

Description of Technology: The 

invention offered here is a vaccine 

candidate that can potentially confer 

protection against many types of 

influenza. Current vaccines against 

influenza virus are comprised of 

inactivated virus or purified influenza 

virus proteins and are targeted primarily 

to induce neutralizing antibodies 

against the viral hemagglutinin (HA) 

protein. The virus can mutate or shift 

antigenic types of HA rapidly rendering 

the vaccines ineffective and thus the 

vaccine has to be evaluated yearly to 

predict next year’s circulating strains for 

vaccine preparation. Unlike HA, the 

small M2 protein is highly conserved 

among different strains of influenza 

virus and thus vaccines based on the M2 

protein have the potential to be effective 

against different strains of influenza. 

The current invention relates to peptide 

vaccines composed of the extracellular 

domain of the M2 protein (M2e) 

conjugated to a carrier protein. In 

animals studies a mutant diphtheria 

toxin-M2e—conjugate induced high 

antibody levels to both vaccine 

components in mice. 

Applications: 

• Preventative and therapeutic for 

influenza virus. 

• Vaccine against seasonal and 

pandemic influenza virus strains. 

Advantages: Novel vaccine candidate 

with potential heterosubtypic 

protection. 

Development Status: In vitro and in 

vivo data can be provided upon request. 

Market: Influenza virus vaccines. 

Inventors: Mark A. Miller (FIC), 

Rachel Schneerson (NICHD), Joanna 

Kubler-Kielb (NICHD), John B. Robbins 

(NICHD), Zuzanna Biesova (NICHD), 

and Jerry Keith (NICHD). 

Patent Status: U.S. Provisional 

Application No. 61/089,384 filed 15 

Aug 2008 (HHS Reference No. E–304– 

2008/0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Kevin W. Chang, 

Ph.D.; 301–435–5018; 

changke@mail.nih.gov. 

Therapeutic HIV Vaccine and 

Associated Protocols 

Description of Technology: This 

technology describes a therapeutic HIV 

DNA vaccine to be administered to 

individuals who have previously 

experienced or are undergoing 

antiretroviral therapy (ART). The 

therapeutic DNA vaccine can also be 

administered in combination with a 

vector encoding an IL–15 and/or IL–15 

receptor alpha (IL–15Ra) polypeptide. In 

primate studies, the technology was 

found to be particularly effective when 

the vaccine composition was 

administered by electroporation and 

expressed six (6) HIV antigens 

(including two (2) gag polypeptides and 

two (2) envelope polypeptides) and IL– 

15 and IL–15Ra. The antigens are 

typically modified with a destabilizing 

sequence, a secretory polypeptide and/ 

or a degradation signal. Successive 

administration up to as many as nine 

resulted in continual boost of the 

immune response against the encoded 

antigen. A potent immunotherapeutic 

vaccine as described here could be an 

important technology for the fight 

against HIV/AIDS. 

Applications: Therapeutic HIV DNA 

vaccines. 

Development Status: Primate data 

available. 

Inventor: Barbara Felber et al. (NCI). 

Patent Status: 

PCT Application No. PCT/US2008/ 

51004 filed 14 Jan 2008, which 

published as WO 2008/089144 on 24 Jul 

2008 (HHS Reference No. E–103–2007/ 

0–PCT–02); claiming priority to 12 Jan 

2007. 

PCT Application No. PCT/US2007/ 

000774 filed 12 Jan 2007, which 

published as WO 2007/084342 on 26 Jul 

2007 (HHS Reference No. E–254–2005/ 

2–PCT–01); claiming priority to 13 Jan 

2006. National Stage filed in AU, BR, 

CA, CN, EP, IL, IN, JP, MX, NZ, and US. 

PCT Application No. PCT/US2001/ 

45624 filed 01 Nov 2001, which 

published as WO 2002/36806 on 10 May 

2002 (HHS Reference No. E–308–2000/ 

0–PCT–02); claiming priority to 01 Nov 

2000. National Stage filed in AU, CA, 

EP, JP, and US. 

U.S. Patent Application No. 11/ 

571,879 filed 09 Jan 2007 (HHS 

Reference No. E–249–2004/1–US–02). 

Licensing Status: Available for 

licensing. 


sroberts on PROD1PC70 with NOTICES
14142 Federal Register / Vol. 74, No. 59 / Monday, March 30, 2009 / Notices 

Licensing Contact: Kevin W. Chang, 

Ph.D.; 301–435–5018; 

changke@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize HIV DNA vaccines. 

Please contact John D. Hewes, Ph.D. at 

301–435–3121 or hewesj@mail.nih.gov 

for more information. 

Dated: March 19, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–6936 Filed 3–27–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the public 

in accordance with the provisions set forth in 

sections 552b(c)(4) and 552b(c)(6), Title 5 

U.S.C., as amended. The grant applications 

and the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, and 

personal information concerning individuals 

associated with the grant applications, the 

disclosure of which would constitute a 

clearly unwarranted invasion of personal 

privacy. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel; NIH Loan Repayment 

Program Regarding Clinical & Pediatric 

Researchers. 

Date: April 29, 2009. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: NIEHS/Keystone Bldg., Keystone 

Building, 530 Davis Drive, Research Triangle 

Park, NC 27709. 

Contact Person: RoseAnne M McGee, 

Associate Scientific Review Administrator, 

Scientific Review Branch, Division of 

Extramural Research and Training, Nat. 

Institute of Environmental Health Sciences, 

P.O. Box 12233, MD EC–30, Research 

Triangle Park, NC 27709. (919) 541–0752. 

mcgee1@niehs.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 

Environmental Health Hazards; 93.114, 

Applied Toxicological Research and Testing, 

National Institutes of Health, HHS) 

Dated: March 23, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–6930 Filed 3–27–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Center for Substance Abuse 

Prevention; Notice of Meeting 

Pursuant to Public Law 92–463, 

notice is hereby given that the 

Substance Abuse and Mental Health 

Services Administration’s (SAMHSA) 

Center for Substance Abuse Prevention 

(CSAP) National Advisory Council will 

meet on April 30, 2009 from 1 p.m. to 

3 p.m. via teleconference. 

The meeting will include discussion 

and evaluation of grant applications 

reviewed by Initial Review Groups. 

Therefore, the meeting will be closed to 

the public as determined by the Acting 

Administrator, SAMHSA, in accordance 

with Title 5 U.S.C. 552b(c)(6) and 5 

U.S.C. App. 2, Section 10(d). 

Substantive program information, a 

summary of the meeting, and a roster of 

Council members may be obtained 

either by accessing the SAMHSA 

Committee’s Web site at https:// 

nac.samhsa.gov/CSAPcouncil/ 

index.aspx as soon as possible after the 

meeting, or by contacting CSAP 

National Advisory Council’s Designated 

Federal Official, Ms. Tia Haynes (see 

contact information below). 

Committee Name: Substance Abuse and 

Mental Health Services Administration, 

Center for Substance Abuse Prevention 

National Advisory Council. 

Date/Time/Type: April 30, 2009, 1 p.m. to 

3 p.m.: CLOSED. 

Place: 1 Choke Cherry Road, Conference 

Room 4–1058, Rockville, Maryland 20857. 

Contact: Tia Haynes, Designated Federal 

Official, SAMHSA/CSAP National Advisory 

Council, 1 Choke Cherry Road, Room 4–1066, 

Rockville, MD 20857, Telephone: (240) 276– 

2436; FAX: (240) 276–2430, E-mail: 

tia.haynes@samhsa.hhs.gov. 

Toian Vaughn, 

Committee Management Officer, Substance 

Abuse and Mental Health, Services 

Administration. 

[FR Doc. E9–6960 Filed 3–27–09; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2009–0192] 

Prince William Sound Regional 

Citizens’ Advisory Council 

(PWSRCAC) Charter Renewal 

AGENCY: Coast Guard, DHS. 

ACTION: Notice of recertification. 

SUMMARY: The purpose of this notice is 

to inform the public that the Coast 

Guard has recertified the Prince William 

Sound Regional Citizens’ Advisory 

Council (PWSRCAC) as an alternative 

voluntary advisory group for Prince 

William Sound, Alaska. This 

certification allows the PWSRCAC to 

monitor the activities of terminal 

facilities and crude oil tankers under the 

Prince William Sound Program 

established by statute. 

DATES: This recertification is effective 

for the period from February 28, 2009, 

through February 28, 2010. 

FOR FURTHER INFORMATION CONTACT: 

LCDR Gary Koehler, Seventeenth Coast 

Guard District, by telephone at (907) 

463–2809, or by mail at 709 W. Ninth 

Street, Juneau, Alaska 99801. 

SUPPLEMENTARY INFORMATION: 

Background and Purpose 

As part of the Oil Pollution Act of 

1990 (OPA 90), Congress passed the Oil 

Terminal and Oil Tanker Environmental 

Oversight and Monitoring Act of 1990 

(the Act), 33 U.S.C. 2732, to foster a 

long-term partnership among industry, 

government, and local communities in 

overseeing compliance with 

environmental concerns in the 

operation of crude oil terminals and oil 

tankers. 

On October 18, 1991, the President 

delegated his authority under 33 U.S.C 

2732(o) to the Secretary of 

Transportation in Executive Order 

12777, section 8(g) (see 56 FR 54757; 

Oct. 22, 1991), for purposes of certifying 

advisory councils, or groups, subject to 

the Act. On March 3, 1992, the Secretary 

redelegated that authority to the 

Commandant of the Coast Guard (see 57 

FR 8582; Mar. 11, 1992). The 


sroberts on PROD1PC70 with NOTICES